Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD, endTB-Q Clinical Trial Team.

Open source

DOI
10.1016/s2213-2600(25)00194-8
Published
2025-07-16
Container
Lancet Respir Med
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-25-00194-8,
  title = {Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.},
  author = {Guglielmetti L and  Khan U and  Velásquez GE and  Gouillou M and  Ali MH and  Amjad S and  Kamal F and  Abubakirov A and  Ardizzoni E and  Baudin E and  Bektassov S and  Berry C and  Bonnet M and  Chavan V and  Coutisson S and  Dakenova Z and  de Jong BC and  Dinh LV and  Ferlazzo G and  Kirakosyan O and  Lachenal N and  Lecca L and  McIlleron H and  Mikanda KK and  Mucching-Toscano S and  Mulders W and  Mushtaque H and  Nahid P and  Nguyen DV and  Nguyen NV and  Oyewusi L and  Motta I and  Panda S and  Patil S and  Pham TH and  Phan DT and  Phan HTT and  Phillips PPJ and  Ruiz J and  Rupasinghe P and  Salahuddin N and  Sanchez-Garavito E and  Seung KJ and  Asfaw MT and  Vargas Vasquez D and  Rich ML and  Varaine F and  Mitnick CD and  endTB-Q Clinical Trial Team.},
  year = {2025},
  journal = {Lancet Respir Med},
  doi = {10.1016/s2213-2600(25)00194-8},
  url = {https://doi.org/10.1016/s2213-2600(25)00194-8}
}

RIS

TY  - JOUR
TI  - Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
AU  - Guglielmetti L
AU  -  Khan U
AU  -  Velásquez GE
AU  -  Gouillou M
AU  -  Ali MH
AU  -  Amjad S
AU  -  Kamal F
AU  -  Abubakirov A
AU  -  Ardizzoni E
AU  -  Baudin E
AU  -  Bektassov S
AU  -  Berry C
AU  -  Bonnet M
AU  -  Chavan V
AU  -  Coutisson S
AU  -  Dakenova Z
AU  -  de Jong BC
AU  -  Dinh LV
AU  -  Ferlazzo G
AU  -  Kirakosyan O
AU  -  Lachenal N
AU  -  Lecca L
AU  -  McIlleron H
AU  -  Mikanda KK
AU  -  Mucching-Toscano S
AU  -  Mulders W
AU  -  Mushtaque H
AU  -  Nahid P
AU  -  Nguyen DV
AU  -  Nguyen NV
AU  -  Oyewusi L
AU  -  Motta I
AU  -  Panda S
AU  -  Patil S
AU  -  Pham TH
AU  -  Phan DT
AU  -  Phan HTT
AU  -  Phillips PPJ
AU  -  Ruiz J
AU  -  Rupasinghe P
AU  -  Salahuddin N
AU  -  Sanchez-Garavito E
AU  -  Seung KJ
AU  -  Asfaw MT
AU  -  Vargas Vasquez D
AU  -  Rich ML
AU  -  Varaine F
AU  -  Mitnick CD
AU  -  endTB-Q Clinical Trial Team.
PY  - 2025
JO  - Lancet Respir Med
DO  - 10.1016/s2213-2600(25)00194-8
UR  - https://doi.org/10.1016/s2213-2600(25)00194-8
ER  -

APA

L, G., U, K., GE, V., M, G., MH, A., S, A., F, K., A, A., E, A., E, B., S, B., C, B., M, B., V, C., S, C., Z, D., BC, D. J., LV, D., G, F., O, K., N, L., L, L., H, M., KK, M., S, M., W, M., H, M., P, N., DV, N., NV, N., L, O., I, M., S, P., S, P., TH, P., DT, P., HTT, P., PPJ, P., J, R., P, R., N, S., E, S., KJ, S., MT, A., D, V. V., ML, R., F, V., CD, M., & Team., E. C. T. (2025). Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.. Lancet Respir Med. https://doi.org/10.1016/s2213-2600(25)00194-8

Source records